100% Discretion & Confidentiality

Wegovy
(Semaglutide)

Wegovy (Semaglutide) is a prescription-only weight loss medication available in the UK, developed by the Danish pharmaceutical company Novo Nordisk. It is administered once weekly via a self-injectable pen and works by mimicking the action of GLP-1 (glucagon-like peptide-1), a naturally occurring hormone involved in appetite regulation and blood sugar control. It is available in five titrational doses, beginning at 0.25 mg and gradually increasing to a maximum dose of 2.4 mg per week. This dose schedule allows the body to adjust to the medication and helps minimise side effects. The treatment supports weight loss by suppressing appetite, prolonging the feeling of fullness, and slowing gastric emptying.

Wegovy Injection Cost Per Dosage

The cost of Wegovy varies depending on the dosage and the quantity of injections purchased.

In Stock Dosages

Wegovy Injection Cost

0.25 mg (4 x doses of 0.25 mg)
£168.00
0.5 mg (4 x doses of 0.5 mg)
£189.00
1.0 mg (4 x doses of 1.0 mg)
£197.00
1.7 mg (4 x doses of 1.7 mg)
£247.00
2.4 mg (4 x doses of 2.4 mg)
£297.00

Start with a Consultation Form

To access Wegovy for weight management, simply complete our medical consultation form with accurate and up-to-date health information. We will carefully review your submission, and if you meet the eligibility criteria, you may proceed with placing an order for Wegovy injections.

Lose Up to 15% Body Weight with Wegovy, Backed by Clinical Studies

Start your weight loss journey by completing a short consultation to see if Wegovy is right for you. Get fast approval and secure home delivery available.

Getting started

Complete our medical consultation form with accurate and up-to-date medical information.
We will assess your provided information to verify your eligibility.
If you meet the eligibility criteria for weight loss treatment, you may then proceed with ordering your Wegovy injections.

Ongoing monthly care

Share your health history and weight loss goals online to get started. A provider will review your info and may order a metabolic lab test before moving forward with treatment.
Share your health history and weight loss goals online to get started. A provider will review your info and may order a metabolic lab test before moving forward with treatment.

Achieve Your Ideal Weight Loss with Wegovy Injection

Wegovy treatment helps you effectively lose up to 15% of your body weight, depending on how well you adhere to the treatment.
Select your current weight
0
Weight you could lose (lbs):
0

During a clinical trial of 68 weeks, Patients lost an average of 15% of their body weight by being on Wegovy, compared to 2.5% in the placebo group. In another study involving 17000 overweight patients, Wegovy demonstrated a 50% reduction in heart-related deaths.

Your Medically Approved Route to Wegovy

From consultation to doorstep, we make your Wegovy weight loss journey safe, secure, and medically compliant.

What is Wegovy?

Wegovy (Semaglutide) is a prescription-only weight loss medication available in the UK, developed by the Danish pharmaceutical company Novo Nordisk. It is administered once weekly via a self-injectable pen and works by mimicking the action of GLP-1 (glucagon-like peptide-1), a naturally occurring hormone involved in appetite regulation and blood sugar control. It comes in five gradual dose steps, starting at 0.25 mg and increasing over time to a maximum of 2.4 mg per week. This dose schedule allows the body to adjust to the medication and helps minimise side effects. The treatment supports weight loss by suppressing appetite, prolonging the feeling of fullness, and slowing gastric emptying.

Eligibility for Wegovy treatment

Wegovy (Semaglutide) is a prescription-based weight loss treatment approved in the UK for individuals who meet specific clinical criteria. It is typically prescribed for adults with a body mass index (BMI) of 30 or above, which falls within the obesity range. It may also be considered for those with a BMI of 27 or higher if they have at least one weight-related health condition, such as type 2 diabetes, cardiovascular disease, high blood pressure, or obstructive sleep apnoea.

Before initiating treatment, a healthcare professional must carry out a comprehensive clinical assessment to evaluate the patient’s medical history, risk factors, and current health status. This ensures the treatment is both appropriate and safe. Wegovy is designed to be used alongside lifestyle changes, such as dietary modifications and physical activity, for sustainable weight management.

However, Wegovy is not suitable for everyone. Individuals with a known allergy to Semaglutide or its components, as well as pregnant or breastfeeding women, should not use this medication due to potential safety concerns. All patients should consult a licensed clinician before starting treatment to confirm eligibility and receive ongoing medical supervision throughout the course of therapy.

Side effects of Wegovy injection

Side effects of Wegovy majorly depend on your body type and immune system. Like all other medications, it has some side effects, some more common than others.

Most Occurring side effects:

  • Headache
  • Loose or frequent bowel movements
  • Constipation
  • Nausea or vomiting
  • Fatigue
  • Abdominal discomfort 

General side effects:

  • Stomach discomfort or mild indigestion
  • Light-headedness
  • Belching
  • Bloating
  • Acid Reflux
  • Hair loss
  • Redness on the injected site
  • Gallstones
  • Gastritis
  • Low blood sugar
  • Altered taste perception
  • Unusual skin sensitivity

Rare side effects

  • Rapid or irregular heartbeat
  • Delayed gastric emptying
  • Shakiness or dizziness
  • Yellowing of the eyes and skin

Serious side effects

Wegovy may cause grave side effects sometimes that require professional supervision immediately, such as:

  • Diabetic retinopathy
  • Inflamed pancreas
  • Kidney or bladder stones
  • Anaphylaxis
  • Bone Fractures
  • Bowel obstruction

How Wegovy differs from Mounjaro

While both Wegovy (semaglutide) and Mounjaro (tirzepatide) are injectable treatments used for weight management, they differ significantly in terms of their active ingredients, mechanism of action, and clinical efficacy.

Wegovy contains semaglutide, a GLP-1 receptor agonist. It works by mimicking the action of glucagon-like peptide-1 (GLP-1), a hormone that helps regulate appetite, slows gastric emptying, and promotes satiety. By acting solely on the GLP-1 receptor, Wegovy effectively reduces hunger and calorie intake, making it a well-established option for weight loss and type 2 diabetes management.

Mounjaro, in contrast, contains tirzepatide, a dual agonist that targets both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. This dual mechanism is thought to provide enhanced metabolic effects, offering greater improvements in insulin sensitivity, appetite regulation, and energy balance. Clinical trials suggest that Mounjaro may result in greater weight loss compared to single agonist therapies like Wegovy. The addition of GIP receptor activation is believed to amplify the overall therapeutic impact, particularly in individuals with obesity and insulin resistance.

Wegovy’s interaction with other medicines

Wegovy (Semaglutide) may interact with certain medications, which is why a thorough consultation with a licensed healthcare provider is essential prior to starting treatment. These interactions can affect the safety and effectiveness of both Wegovy and any concurrent medications, particularly those used for managing Type 2 diabetes.

One of the most notable interactions is with insulin and sulfonylureas, both of which are commonly prescribed to lower blood glucose. When taken in combination with Wegovy, these medications can increase the risk of hypoglycaemia (low blood sugar). To mitigate this, your doctor may adjust the dose of your insulin or sulfonylurea therapy while prescribing Wegovy to ensure a safe and balanced treatment plan.

Additionally, Wegovy should not be used in combination with other GLP-1 receptor agonists, such as Liraglutide (e.g., Saxenda) or Tirzepatide (Mounjaro). Using multiple GLP-1 based medications simultaneously does not enhance efficacy and may increase the risk of side effects or complications. Always inform your healthcare provider of all medications you are currently taking, including prescriptions, over-the-counter treatments, and supplements, to ensure safe prescribing practices.

What our patients say about Weight Loss Pharmacy

Frequently Asked Questions

Wegovy is suitable for long-term weight management, and there is no fixed duration for treatment. Most patients continue using it until they reach a healthy, sustainable weight, which may take several months to over a year. Ongoing use should always be monitored by a healthcare provider to ensure it’s still effective, well-tolerated, and aligned with your health goals.
Wegovy contains Semaglutide, a medication that mimics the action of GLP-1, a natural hormone involved in appetite regulation. It works by helping you feel full sooner, reducing hunger, slowing down digestion, and lowering cravings. These combined effects lead to reduced calorie intake, making it easier to lose weight while following a healthy lifestyle.
Yes, in many cases, patients may switch from Ozempic to Wegovy, especially when the goal is focused more on weight management than blood sugar control. Both medications contain Semaglutide, but Wegovy is specifically approved and dosed for weight loss. Any switch between the two should be done under medical supervision to ensure the correct dosage and avoid side effects.
To support faster and more effective weight loss with Wegovy, it’s important to combine the treatment with healthy lifestyle changes. Focus on eating a nutrient-rich, calorie-controlled diet, staying physically active, keeping hydrated, and getting enough sleep. Avoid processed foods, sugary drinks, and emotional eating. Always follow your prescriber’s advice and do not adjust the dosage on your own.

Did You Know?

Besides Wegovy’s weight loss benefits, the FDA further highlighted its cardiovascular benefits in March 2024, : Wegovy now also reduces the risk of heart attacks, strokes, and cardiovascular death in people who are overweight or obese with heart disease

Dr Mihaela C. is a highly experienced General Practitioner registered with the General Medical Council (GMC No. 7099398), with a strong background in both NHS and private healthcare across the UK. Her clinical expertise spans general medicine, occupational health, weight management, and medico-legal reporting. As part of her commitment to improving long-term health outcomes, Dr Mihaela offers medically supervised weight loss treatment designed to support patients in achieving sustainable, safe, and effective results. Her approach is rooted in clinical evidence and focuses on understanding each patient’s unique medical profile, lifestyle, and goals to develop personalised care plans.
Last reviewed on: 18/07/2025

Take Next Step

Let’s talk about how we can work together to make healthcare work for all of us.

Subscribe to Our Newsletter